

# ***Role of FDG PET-CT in evaluation of Gastrointestinal stromal tumors (GIST)***

*Thesis*

Submitted for fulfillment of master degree in  
Nuclear Medicine

*By*

***Gihan Essam El-Din El-Hennawy***

*(M.B., B.Ch)*

*Under supervision of*

***Prof. Dr. Hosna Moustafa***

Professor of Nuclear Medicine  
Faculty of Medicine Cairo University

***Dr. Hoda Fathy El-Sayed***

Lecturer of Nuclear Medicine  
NCI , Cairo University

***Dr. Esraa Ahmed El-Kholy***

Lecturer of Nuclear Medicine  
NCI , Cairo University

*Faculty of medicine*

*Cairo University*

***2016***

## *Acknowledgment*

*In the name of **Allah**, the Most Gracious and the Most Merciful .*

*Alhamdulillah, all praises to **Allah** for the strengths and His blessing in completing this thesis.*

*I have the honor to present this work under the supervision of Prof. Dr. **Hosna Moustafa** professor of nuclear medicine, Cairo University . I am very grateful for her continuous care , meticulous supervision , valuable comments and scientific methodology without her continuous guidance and sincere devotion this work couldn't be accomplished.*

*I would like to express my sincere gratitude to Dr. **Hoda Fathy** , lecturer of nuclear medicine, National cancer institute, Cairo University, for supervising this thesis , she helped me a lot in collecting the cases .*

*I wish to express my great appreciation and gratitude to Dr. **Esraa El-Kholy** , lecturer of nuclear medicine, National cancer institute, Cairo University, every word and every step in this work have been kindly arranged and revised by her sincere advice , effort and care .*

*Last but not least, words are not enough to thank my beloved **parents** for their continuous care, love and unlimited support . Thank you for encouraging me in all of my pursuits and inspiring me to follow my dreams.*

## **LIST OF CONTENTS**

<b><i>No.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
<b>1</b>	<b>List of Abbreviations</b>	<b><i>I</i></b>
<b>2</b>	<b>List of Figures</b>	<b><i>II-III</i></b>
<b>3</b>	<b>List of Tables</b>	<b><i>IV-V</i></b>
<b>4</b>	<b>Introduction</b>	<b><i>1-2</i></b>
<b>5</b>	<b>Aim of the work</b>	<b><i>3</i></b>
<b>6</b>	<b>Epidimiology</b>	<b><i>4-5</i></b>
<b>7</b>	<b>Pathology of GIST</b>	<b><i>6-13</i></b>
<b>8</b>	<b>Diagnosis of GIST</b>	<b><i>14-21</i></b>
<b>9</b>	<b>PET/CT imaging in GIST</b>	<b><i>22-32</i></b>
<b>10</b>	<b>Treatment of GIST</b>	<b><i>33-37</i></b>
<b>11</b>	<b>Patients and methods</b>	<b><i>38-44</i></b>
<b>12</b>	<b>Results</b>	<b><i>45-65</i></b>
<b>13</b>	<b>Case presentation</b>	<b><i>66-74</i></b>
<b>14</b>	<b>Discussion</b>	<b><i>78-86</i></b>
<b>15</b>	<b>Conclusions</b>	<b><i>87</i></b>
<b>16</b>	<b>Recommendations</b>	<b><i>88</i></b>
<b>17</b>	<b>Summary</b>	<b><i>89-91</i></b>
<b>18</b>	<b>References</b>	<b><i>92-102</i></b>
<b>19</b>	<b>Arabic Summary</b>	<b><i>—</i></b>

---

---

# ABSTRACT

Imatinib mesylate is a selective, potent, small molecule inhibitor of a family of structurally related tyrosine kinase signaling enzymes . For recurrent or metastatic GIST, the standard of care is treatment with imatinib , the appropriate initial dose is 400 mg/d . Moreover , patients can be treated with neo-adjuvant Imatinib until the optimal time for surgery (when the GIST becomes resectable and the chance of morbidity is acceptable) .

In the present study we attempted to compare the performance of diagnostic CT and F-18 FDG PET/CT in staging and assessment of therapy response of 47 consecutive patients, 18 patients was non metastatic, while the remaining 29 patients had dominating liver, peritoneal and nodal deposits ( mean age :  $49.2 \pm 12.7$  ) with histologically proven GIST. A clinical/radiological CT and PET/CT follow-up of 3-15 months duration served as standards of reference.

Diagnostic CT and PET/CT show comparable results in initial staging , although PET/CT was able to detect more lesions per patient (subcentimetric lymph nodes, few additional peritoneal deposits and marrow based metastases) missed by radiologists, this difference in performance did not had a significant statistical difference. Yet , when planning to assess therapy response with PET CT , a baseline study is essential as approximately 20% of lesions are not FDG avid in initial study .

## Keywords

***Role of FDG PET-CT in evaluation of Gastrointestinal stromal tumors (GIST)***

## **LIST O ABBREVIATIONS**

<b><i>Abbrev.</i></b>	<b><i>Full Term</i></b>
<b>CT</b>	Computed tomography
<b>CMR</b>	Complete metabolic response
<b>EUS</b>	Endoscopic ultrasound
<b>EORTC</b>	The European Organisation for Research and Treatment of Cancer
<b>FNA</b>	Fine needle aspiration
<b>FDG</b>	18F-2-fluoro-2-deoxy-d-glucose
<b>GISTs</b>	Gastrointestinal stromal tumors
<b>GIT</b>	Gastrointestinal tract
<b>68Ga</b>	Gallium-68
<b>HU</b>	Hounsfield unit
<b>HAE</b>	Hepatic arterial embolization
<b>ICCs</b>	Interstitial cells of Cajal
<b>IM</b>	Imatinib Mesylate
<b>MRI</b>	Magnetic resonance imaging
<b>NCCN</b>	The National Comprehensive Cancer Network
<b>PERCIST</b>	PET Response Criteria in Solid Tumors
<b>PDGFRA</b>	Platelet-derived growth factor receptor alpha
<b>PET</b>	Positron emission tomography
<b>PMR</b>	Partial metabolic response
<b>PMD</b>	Progressive metabolic disease
<b>ROI</b>	Region of interest
<b>RECIST</b>	Response Evaluation Criteria In Solid Tumors
<b>SEER</b>	Surveillance, Epidemiology, and End Results
<b>SUV</b>	The standardized uptake value
<b>SUL</b>	Standardized uptake value (SUV) normalized by lean body mass
<b>SMD</b>	Stable metabolic disease
<b>TNB</b>	True cut needle biopsy
<b>TKI</b>	Tyrosine Kinase Inhibitors
<b>TLG</b>	Total lesion glycolysis
<b>UICC</b>	The international union against cancer

## **LIST OF FIGURES**

<b><i>No.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
<b><i>1.</i></b>	Macroscopic finding of the tumor.	<b><i>7</i></b>
<b><i>2.</i></b>	Spindle cell gastrointestinal stromal tumor.	<b><i>8</i></b>
<b><i>3.</i></b>	Epithelioid cell gastrointestinal stromal tumor.	<b><i>8</i></b>
<b><i>4.</i></b>	A schematic illustration of a PET/CT system	<b><i>23</i></b>
<b><i>5.</i></b>	Normal distribution of FDG in PET CT	<b><i>23</i></b>
<b><i>6.</i></b>	18F-FDG PET and CT scans of patient with metastatic GIST in abdomen and liver before therapy and after imatinib mesylate .	<b><i>26</i></b>
<b><i>7.</i></b>	Site of primary GIST in a total number of 47 patients included in the study .	<b><i>45</i></b>
<b><i>8.</i></b>	Distribution of site/organ metastases in 47 patients with GIST .	<b><i>47</i></b>
<b><i>9.</i></b>	Site of primary GIST in 18 patients with initial and follow up PET CT.	<b><i>52</i></b>
	<b><i>Case Presentation</i></b>	
<b><i>10.</i></b>	PET/CT axial fused images revealed metabolically active FDG avid gastric fungating mass with multiple FDG avid hepatic , bone and peritoneal deposits .	<b><i>66</i></b>
<b><i>11.</i></b>	PET/CT axial fused images revealed FDG avid intra medullary deposits with no cortical disruption in CT.	<b><i>67</i></b>
<b><i>12.</i></b>	PET/CT Coronal fused images revealed metabolically inactive large hypodense hepatic focal lesion measuring 7 cm in maximum diameter .	<b><i>68</i></b>
<b><i>13.</i></b>	PET/CT Coronal fused images revealed metabolic activity in some of the hepatic focal lesions and no appreciable FDG uptake in other HFLs as well as multiple Metabolically active FDG avid para aortic lymph nodes.	<b><i>69</i></b>

<b>14.</b>	Axial cuts of FDG PET/CT fused images shows two metabolically active FDG avid peritoneal deposits at baseline study and complete metabolic remission of the still CT detected residual peritoneal deposits after 4 months of target therapy.	<b>71</b>
<b>15.</b>	PET/CT axial fused images revealed no appreciable FDG uptake in the Pararectal mass ( false negative PET/CT results ) proved by pathology .	<b>72</b>
<b>16.</b>	PET/CT axial fused images revealed Stationary course regarding the size of the hepatic focal lesions with no appreciable FDG uptake.	<b>73</b>
<b>17.</b>	PET/CT axial fused images revealed Stationary course regarding the size of the hepatic focal lesions with no appreciable FDG uptake.	<b>74</b>

## **LIST OF TABLES**

<b><i>No.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
<b>1</b>	<b>TNM classification for GIST .</b>	<b>11</b>
<b>2</b>	<b>Modified CT response criteria .</b>	<b>19</b>
<b>3</b>	<b>Patients characteristics in 47 patients with GIST.</b>	<b>46</b>
<b>4</b>	<b>Distribution of site/organ metastases in 47 patients with GIST .</b>	<b>48</b>
<b>5</b>	<b>Risk stratification in 23 patients with GIST :</b>	<b>49</b>
<b>6</b>	<b>Summary comparing results of PET CT and follow up</b>	<b>51</b>
<b>7</b>	<b>Distribution of metastatic sites in 18 patients on initial staging :</b>	<b>53</b>
<b>8</b>	<b>Frequency of metastatic sites using 18F-FDG PET CT and CT Scans in initial staging</b>	<b>54</b>
<b>9</b>	<b>Analysis of patients in initial staging by PET/CT and diagnostic CT.</b>	<b>55</b>
<b>10</b>	<b>Sensitivity , specificity , positive Predictive and negative predictive values of PET/CT and diagnostic CT in initial staging .</b>	<b>55</b>
<b>11</b>	<b>Results of 18F-FDG PET/CT and CT Scan .</b>	<b>56</b>
<b>12</b>	<b>Analysis of 225 lesions in 47 patients with GIST.</b>	<b>58</b>
<b>13</b>	<b>SUVmax and mean , median size of lesions :</b>	<b>58</b>
<b>14</b>	<b>Comparative analysis of 40 lymph node lesions in PET/CT and diagnostic CT in 40 lymph node lesions .</b>	<b>60</b>

---

---



<b>15</b>	<b>Sensitivity and positive Predictive value of PET/CT and diagnostic CT in 40 lymph node lesions .</b>	<b>60</b>
<b>16</b>	<b>Distribution of 50 peritoneal lesions in PET CT and diagnostic CT .</b>	<b>62</b>
<b>17</b>	<b>Sensitivity and Positive Predictive value of PET/CT and diagnostic CT in 50 peritoneal deposits .</b>	<b>62</b>
<b>18</b>	<b>Frequency of liver deposits in 42 lesions before treatment</b>	<b>63</b>
<b>19</b>	<b>Sensitivity and Positive Predictive value of PET/CT and diagnostic CT in 42 liver lesions before treatment .</b>	<b>64</b>
<b>20</b>	<b>Frequency table of liver deposits in 71 lesions after treatment</b>	<b>65</b>
<b>21</b>	<b>Sensitivity and Positive Predictive value of PET/CT and diagnostic CT in 71 liver lesions after treatment.</b>	<b>65</b>

# *Introduction*

Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract (1).

The first accurate description of mesenchymal neoplasms of the gastrointestinal tract (GIT) was in 1941. Traditionally, these tumors were thought to be derived from smooth muscle cells, based on their resemblance to smooth muscle tumors and they were designated as leiomyomas, bizarre leiomyomas, cellular leiomyomas and leiomyosarcomas. However, with the advent of electron microscopy, it has been shown that many of these neoplasms lacked the immunophenotypical features of smooth muscle differentiation (2) .

With the advent of immunohistochemical analysis a definition of a new entity among the gastrointestinal mesenchymal tumors called the gastrointestinal stromal tumors (GISTs) which particularly express the kit (CD117) protein a growth factor trans-membrane receptor with tyrosine kinase activity (3).

Surgery is the mainstay of therapy for non metastatic GISTs. Laparoscopic surgery has been shown to be effective for removal of these tumors without the need of large incisions(4).

The c-kit tyrosine kinase inhibitor Imatinib (Glivec/Gleevec), a drug initially marked for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. Patients who become refractory on Imatinib may respond to the multiple tyrosin kinase inhibitor sunitinib (Sutent) (5).

The current Response Evaluation Criteria in solid tumors are based on uni-dimensional tumor size, and do not take into account changes in responding GISTs such as a decrease in tumor density and decrease in the number of intratumoral vessels with computed tomography (CT) . Modified CT criteria using a combination of tumor density and tumor size are promising in early response evaluation, and have excellent prognostic value (6) .

Positron emission tomography (PET) has been found to be highly sensitive in assessment early response to Imatinib mesylate . Also , it is useful in predicting long-term response to imatinib in patients with metastatic GIST; however, widespread use of PET is limited because of cost constraints (7).

## ***AIM OF WORK***

The aim of this study was to evaluate the feasibility, utility, and efficacy of 18FDG-PET/CT in staging patients affected by GIST , those who were treated by surgery or imatinib mesylate and comparing the results with diagnostic CT for a validation.

## ***Epidemiology of GIST***

***Incidence of GIST:*** Gastrointestinal stromal tumors (GISTs) account for less than 1% of gastrointestinal tumors, however, are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs are usually found in the stomach or small intestine but can occur anywhere along the gastrointestinal tract and rarely have extra-gastrointestinal involvement (7) .

GISTs rank a distant third in prevalence behind adenocarcinomas and lymphomas among the histologic types of gastrointestinal tract tumors (8) .

***Age and Sex :*** predominantly occur in middle aged and older patients (fifth to seventh decades (9) .

SEER (Surveillance, Epidemiology, and End Results) analysis of 1,458 cases from 1992 to 2000 data reported a slightly higher prevalence in males versus females, at 54% and 46%, respectively (10) .

***Anatomical Location of GIST:*** GISTs are usually found in the stomach or small intestine but can occur anywhere along the gastrointestinal tract and rarely have extra-gastrointestinal involvement. The size of the tumor may be smaller than 1 cm or as large as 40 cm in diameter.

Approximately 50-70% of GISTs originate in the stomach. The small intestine is the second most common location, with 20-30% of GISTs arising from the jejunum-ileum. Less frequent sites of occurrence include the colon and rectum (5-15%) and esophagus (< 5%). Primary

pancreatic, omental, or mesenteric GISTs have been reported but are very rare (7) .

The distribution of GISTs in the stomach is as follows: pars media (40%); antrum (25%); pylorus (20%); submucosa (60%); subserosa (30%); and intramural (10%) (11) .

Less than 1 % of GISTs initially occur outside of these organs (12) . These tumors submucosal lesions, which most frequently grow endophytically in parallel with the lumen of the affected structure (10).

***Mortality/Morbidity:*** Outcomes in patients with GISTs are highly dependent on the clinical presentation and the histopathological features of the tumor. The overall 5-year survival rate ranges from 28-60%. This can be stratified for patients presenting with localized primary disease and those presenting with metastatic or recurrent disease. The median survival rate in the former group is 5 years, while the median survival rate in the latter group is approximately 10-20 months (8) .

# ***Pathology of GIST***

## ***Cells of Origin of GIST "ICCS":***

GISTs have been misclassified as leiomyomas, leiomyosarcomas and leiomyoblastomas. With the advent of immunohistochemistry and electron microscopy, it was discovered that GIST cells of origin are probably related not to smooth muscle cells but to the cells of Cajal (13) .

According to the work of Kindblom (13) , the actual cell of origin of GISTs is a pluripotential mesenchymal stem cell programmed to differentiate into the interstitial cell of Cajal. These are GI pacemaker cells found in the muscularis propria and around the myenteric plexus and are largely responsible for initiating and coordinating GI motility .

Both GIST cells and cells of Cajal have been shown to express the cell surface receptor C-kit, which is identified by CD117 . C-kit functions as a tyrosine kinase, which is activated as a ligand in the presence of a stem cell factor (14). In 1998, Hirota et al. reported a mutation of the C-kit proto-oncogene that activates tyrosine kinase in the absence of a stem cell factor, leading to uncontrolled cell proliferation (15) .

## ***Gross Pathological Features:***

GISTs range in size from incidental lesions a few millimeters in diameter to large masses of 35 cm or more; the median size at presentation is about 5 cm. The tumors are generally centered on the bowel wall but may form polypoid serosal- or mucosal-based masses (16). Ulceration of the mucosa is often associated with GI bleeding.